New therapeutic strategies for BRAF mutant colorectal cancers.

Abstract excerpt

Oncogenic BRAF mutations are found in ~10% of colorectal cancers (CRCs) and predict poor prognosis. Although BRAF inhibitors have demonstrated striking efficacy in BRAF mutant melanomas, BRAF inhibitor monotherapy is ineffective in BRAF mutant CRC. Over the past few years, studies have begun to define the molecular mechanisms underlying the relative resistance of BRAF mutant CRC to BRAF inhibitors, leading to the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Research and Treatments
• Share to Colorectal Cancer Treatments and Studies
• Share to Melanoma and MAPK Pathways